Nippon Shinyaku | search
Click here to view Nippon Shinyaku news from 60+ newspapers.
Bookmark or Share- To Our Shareholders and Investors | Nippon ShinyakuTo Our Shareholders. and Investors. Stock Quote. TSE Prime: 4516. 2024/05/09 15:00. Last 4,413. Change 0 (0.00%) Stock Price chart. Top.
- Nippon Shinyaku Co., Ltd. (4516) Stock Price & News - GoogleGet the latest Nippon Shinyaku Co., Ltd. (4516) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
- Vicore and Nippon Shinyaku Enter into an Exclusive License Agreement to ...Stockholm, February 9, 2024 – Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), today announced it has entered into an exclusive licensing agreement with Nippon Shinyaku Co. Ltd., a leading Japanese pharmaceutical company, to develop and commercialize ...
- Main Products │ Pharmaceuticals Division │ Who we are │ NIPPON SHINYAKU ...CD20-positive chronic lymphocytic leukemia. Gazyva. For myelodysplastic syndrome or Acute Myeloid Leukemia. Vidaza. For relapsed or refractory acute promyelocytic leukemia. Amnolake. For relapsed or refractory acute promyelocytic leukemia. Trisenox. For relapsed or refractory acute leukemia and malignant lymphoma.
- Who we are │ NIPPON SHINYAKU CO., LTD.Who we are. Nippon Shinyaku aims to be trusted and respected by society as a company that plays a meaningful role in the healthcare sector.
More
